Table 2 Baseline characteristics of the patients with and without DIC diagnosed by ISTH overt DIC criteria treated or untreated with anticoagulants
From: Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan
|  | Non-DIC (n = 2037) | DIC (n = 626) | ||||
|---|---|---|---|---|---|---|
|  | Anticoagulant group (n = 814) | Control group (n = 1223) | P value | Anticoagulant group (n = 433) | Control group (n = 193) | P value |
Patient characteristics | ||||||
 Age in years | 72 (63–80) | 73 (63–81) | 0.127 | 72 (61–80) | 73 (63–82) | 0.314 |
 Male sex | 485 (60 %) | 743 (61 %) | 0.611 | 231 (53 %) | 117 (61 %) | 0.098 |
Illness severity | ||||||
 SIRS score | 3 (2–4) | 3 (2–4) | 0.522 | 3 (3–4) | 3 (3–4) | 0.078 |
 SOFA score | 9 (7–12) | 7 (5–10) | <0.001 | 12 (9–14) | 12 (9–15) | 0.520 |
 APACHE II score | 23 (17–28) | 20 (15–26) | <0.001 | 25 (19–30) | 24 (18–33) | 0.342 |
 ISTH DIC score | 3 (2–4) | 2 (1–3) | <0.001 | 6 (5–6) | 6 (5–6) | 0.411 |
 JAAM DIC score | 4 (3–5) | 2 (1–4) | <0.001 | 7 (6–8) | 6 (5–8) | 0.004 |
Source of ICU admission | Â | Â | <0.001 | Â | Â | 0.395 |
 Emergency department | 349 (43 %) | 639 (52 %) | - | 178 (41 %) | 90 (47 %) | - |
 Ward | 233 (29 %) | 294 (24 %) | - | 133 (31 %) | 51 (26 %) | - |
 Other hospital | 232 (29 %) | 290 (24 %) | - | 122 (30 %) | 52 (27 %) | - |
Pre-existing condition | ||||||
 Liver insufficiency | 7 (0.9 %) | 3 (0.2 %) | 0.100 | 5 (1 %) | 4 (2 %) | 0.468 |
 Chronic heart failure | 49 (6 %) | 60 (5 %) | 0.315 | 27 (6 %) | 7 (4 %) | 0.251 |
 Chronic respiratory disorder | 31 (4 %) | 50 (4 %) | 0.817 | 11 (3 %) | 10 (5 %) | 0.097 |
 Chronic haemodialysis | 54 (7 %) | 98 (8 %) | 0.264 | 30 (7 %) | 27 (14 %) | 0.006 |
 Immunocompromised | 86 (11 %) | 134 (11 %) | 0.827 | 44 (10 %) | 16 (8 %) | 0.557 |
New organ dysfunction (SOFA sub-scores ≥2) | ||||||
 Respiratory | 565 (69 %) | 812 (66 %) | 0.161 | 286 (66 %) | 129 (67 %) | 0.927 |
 Cardiovascular | 605 (74 %) | 681 (56 %) | <0.001 | 329 (76 %) | 146 (76 %) | 0.920 |
 Renal | 416 (51 %) | 454 (37 %) | <0.001 | 291 (67 %) | 118 (61 %) | 0.147 |
 Hepatic | 114 (14 %) | 136 (11 %) | 0.054 | 139 (32 %) | 52 (27 %) | 0.222 |
 Coagulation | 239 (29 %) | 226 (19 %) | <0.001 | 352 (81 %) | 140 (73 %) | 0.015 |
Primary source of infection | Â | Â | <0.001 | Â | Â | 0.257 |
 Abdomen | 304 (37 %) | 342 (28 %) | - | 156 (36 %) | 79 (41 %) | - |
 Lung | 205 (25 %) | 383 (31 %) | - | 64 (15 %) | 25 (13 %) | - |
 Urinary tract | 113 (14 %) | 199 (16 %) | - | 108 (25 %) | 36 (19 %) | - |
 Bone/soft tissue | 102 (13 %) | 145 (12 %) | - | 44 (10 %) | 18 (9 %) | - |
 Central nervous system | 15 (2 %) | 22 (2 %) | - | 15 (4 %) | 5 (3 %) | - |
 Other/unknown | 75 (9 %) | 132 (11 %) | - | 46 (11 %) | 30 (16 %) | - |
Other therapeutic interventions | ||||||
 Immunoglobulin | 377 (46 %) | 179 (15 %) | <0.001 | 213 (49 %) | 31 (16 %) | <0.001 |
 Low-dose steroid | 248 (31 %) | 184 (15 %) | <0.001 | 153 (35 %) | 39 (20 %) | <0.001 |
 Renal replacement therapy | 351 (43 %) | 204 (17 %) | <0.001 | 215 (50 %) | 60 (31 %) | <0.001 |
 PMX-DHP | 251 (31 %) | 137 (11 %) | <0.001 | 159 (37 %) | 27 (14 %) | <0.001 |
 Surgical intervention | 415 (51 %) | 458 (37 %) | <0.001 | 202 (47 %) | 78 (40 %) | 0.164 |